Are we at a stage to predict autoimmune rheumatic diseases?

Arthritis and Rheumatism

Volumn 56, Issue 6, 2007, Pages 1736-1744

  Bizzaro, Nicola ^b   Tozzoli, Renato ^b   Shoenfeld, Yehuda ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b Ospedale Civile   (Italy)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; CENTROMERE ANTIBODY; LA ANTIBODY; NUCLEOSOME ANTIBODY; RHEUMATOID FACTOR; RO ANTIBODY; AUTOANTIBODY; AUTOANTIGEN; RIBONUCLEOPROTEIN; SS A ANTIGEN; SS B ANTIGEN; SS-A ANTIGEN; SS-B ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; CONNECTIVE TISSUE DISEASE; DISEASE SEVERITY; HUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; IMMUNOLOGY; NUCLEOSOME; PHYSIOLOGY; PREDICTION AND FORECASTING;

ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; HUMANS; NUCLEOSOMES; PREDICTIVE VALUE OF TESTS; RHEUMATIC DISEASES; RHEUMATOID FACTOR; RIBONUCLEOPROTEINS;

EID: 34249870401     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22708     Document Type: Review

References (75)

1. Vanderpump MP, Turnbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickam Survey. Clin Endocrinol 1995;43:55-68.
2. Betterle C, Volpato M, Rees Smith B, Furmaniak J, Chen S, Zanchetta R, et al. II. Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison's disease. J Clin Endocrinol Metab 1997;82:939-42.
3. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
4. Majka DS, Holers VM. Can we accurately predict the development of rheumatoid arthritis in the preclinical phase? [editorial]. Arthritis Rheum 2003;48:2701-5.
5. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
6. Swaak T, Smeenk R. Detection of anti-dsDNA as a diagnostic tool: a prospective study in 441 non-systemic lupus erythematosus patients with anti-dsDNA antibody (anti-dsDNA). Ann Rheum Dis 1985;44:245-51.
7. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the preliminary classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
8. McClain MT, Arbuckle MR, Heinlen LD, Dennis GJ, Roebuck J, Rubertone MV, et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004;50:1226-32.
9. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
10. Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, Ugalde J, Aguirre C. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus 2004;13:900-5.
11. Harel M, Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality? Ann N Y Acad Sci 2006;1069:322-45.
12. Alarcon-Segovia D, Boffa MC, Branch W, Cervera R, Gharavi A, Khamashta M, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 2003;12:499-503.
13. Abraham-Simon J, Rojas-Serrano J, Cabiedes J, Alcocer-Varela J. Antinucleosome antibodies may help predict development of systemic lupus erythematosus in patients with primary antiphospholipid syndrome. Lupus 2004;13:177-81.
14. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. Ann Rheum Dis 1993;55:116-21.
15. Von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24: 323-58.
16. Routsias JG, Tzioufas AG. SS-B(La) autoantibodies. In: Shoenfeld Y, Gershwin ME, Meroni PL, editors. Autoantibodies. Amsterdam: Elsevier Science BV; 2006. p. 239-46.
17. Reichlin M, Scofield RH. SS-A(Ro) autoantibodies. In: Shoenfeld Y, Gershwin ME, Meroni PL, editors. Autoantibodies. Amsterdam: Elsevier Science BV; 2006. p. 225-30.
18. Buyon JP, Winchester R. Congenital heart block: a human model of passively acquired autoimmune injury. Arthritis Rheum 1990; 33:609-14.
19. Buyon JP. Neonatal lupus syndromes. Am J Reprod Immunol 1992;28:259-63.
20. McCune AB, Weston WL, Lee LA. Maternal and fetal outcome in neonatal lupus erythematosus. Ann Intern Med 1987;106:518-23.
21. Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994; 120:544-52.
22. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
23. Iijima T, Tada H, Hidaka Y, Yagoro A, Mitsuda N, Kanzaki T, et al. Prediction of postpartum onset of rheumatoid arthritis. Ann Rheum Dis 1998;57:460-3.
24. Del Puente A, Knowler WC, Pettitt DJ, Bennett PH. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum 1988;31: 1239-44.
25. Saraux A, Berthelot JM, Chales G, Le Henaff C, Mary JY, Thorel JB, et al. Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 2002;47:155-65.
26. Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005;64:1731-6.
27. Aho K, Heliovaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 1991;18:1282-4.
28. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
29. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001;47:1089-93.
30. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
31. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
32. Mandl LA, Costenbader K, Chibnik L, Schur P, Karlson EW. Anti-cyclic citrullinated peptide (anti-CCP) antibodies are strongly associated with risk of rheumatoid arthritis after adjusting for hormonal and behavioral factors [abstract]. Arthritis Rheum 2005;52 Suppl 9:S732.
33. Deane KD, Majka DS, Parrish LA, Baron AE, Gilliland WR, Walker CW, et al. RA-related antibodies appear earlier in the pre-clinical period in subjects with an older age at disease onset [abstract]. Arthritis Rheum 2005;52 Suppl 9:S154.
34. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma IE, van der Stadt RJ, de Koning MH, Dijkmans BA. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 2003;30:1691-5.
35. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
36. Van Gaalen FA, Linn-Rasker S, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.
37. Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D, et al. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 2004;135:173-80.
38. Russell AS, Devani A, Maksymowych WP. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J Rheumatol 2006;33: 1240-2.
39. Weiner ES, Hildebrandt S, Senecal JL, Daniels L, Noell S, Joyal F, et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease: a prospective study. Arthritis Rheum 1991;34:68-77.
40. Sarkar K, Miller FW. Autoantibodies as predictive and diagnostic markers of idiopathic inflammatory myopathies. Autoimmunity 2004;37:291-4.
41. Miller FW, Waite KA, Biswas T, Plotz PH. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci U S A 1990;87: 9933-7.
42. Targoff IN, Trieu EP, Plotz PH, Miller FW. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992;35:821-30.
43. Wagner U, Kaltenhauser S, Sauer H, Arnold S, Seidel W, Hantzschel H, et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997;40: 341-51.
44. Shepshelovich D, Shoenfeld Y. Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity. Lupus 2006;15:183-90.
45. Van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004;50:2113-21.
46. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;171:538-41.
47. Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund G, van Venrooij WJ, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with the future onset of rheumatoid arthritis. Arthritis Res Ther 2004;6:R303-8.
48. Liblau RS, Bach JF. Selective IgA deficiency and autoimmunity. Int Arch Allergy Immunol 1992;99:16-27.
49. Etzioni A. Immune deficiency and autoimmunity. Autoimmun Rev 2003;2:364-9.
50. Boackle SA, Holers VM. Role of complement in the development of autoimmunity. Curr Dir Autoimmun 2003;6:154-68.
51. Robinson WH, Steinman L, Utz PJ. Proteomics technology for the study of autoimmune disease [review]. Arthritis Rheum 2002;46: 885-93.
52. Venkatasubbarao S. Microarrays - status and prospects. Trends Biotechnol 2004;22:630-7.
53. Tozzoli R, Bizzaro N. Novel diagnostic methods for autoantibody detection. In: Shoenfeld Y, Gershwin ME, Meroni PL, editors. Autoantibodies. Amsterdam: Elsevier Science BV; 2006. p. 77-82.
54. Fritzler MJ. Advances and applications of multiplexed diagnostic technologies in autoimmune diseases. Lupus 2006;15:422-7.
55. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002;8:295-301.
56. Hueber W, Kidd BA, Tomooka BH, Lee BJ, Bruce B, Fries JF, ct al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 2005;52:2645-55.
57. Feng Y, Ke X, Ma R, Chen Y, Hu G, Liu F. Parallel detection of autoantibodies with microarrays in rheumatoid diseases. Clin Chem 2004;50:416-22.
58. Meheus L, van Venrooij WJ, Wiik A, Charles PJ, Tzioufas AG, Meyer O, et al. Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol 1999;17:205-14.
59. Pottel H, Wiik A, Locht H, Gordon T, Robert-Thompson P, Abraham D, et al. Clinical optimization and multicenter validation of antigen-specific cut-off values on the INNO-LIA ANA update for the detection of autoantibodies in connective tissue disorders. Clin Exp Rheumatol 2004;22:579-88.
60. Eissfeller P, Sticherling M, Scholz D, Hennig K, Luttich T, Motz M, et al. Comparison of different test systems for simultaneous autoantibody detection in connective tissue diseases. Ann N Y Acad Sci 2005;1050:327-39.
61. Rouquette AM, Desgruelles C, Laroche P. Evaluation of the new multiplexed immunoassay, FIDIS, for simultaneous quantitative determination of antinuclear antibodies and comparison with conventional methods. Am J Clin Pathol 2003;120:676-81.
62. Tozzoli R, Kodermaz G, Tonutti E, Bizzaro N, Villalta D. Diagnostic accuracy of the FIDIS multiplex immunoassay system for the detection of gliadin and transglutaminase antibodies in celiac disease (abstract). Autoimmun Rev 2004;3 Suppl 2:127.
63. Tozzoli R, Kodermaz G, Bizzaro N, Bagnasco M, Villalta D, Tonutti E. Autoantibody profiling of AITD patients using a new multiplexed immunoassay system. Clin Chem Lab Med 2006;44: 837-42.
64. Gilburd B, Abu-Shakra M, Shoenfeld Y, Giordano A, Bocci EB, delle Monache F, et al. Autoantibodies profile in the sera of patients with Sjogren's syndrome: the ANA evaluation - a homogeneous, multiplexed system. Clin Dev Immunol 2004;11:53-6.
65. Shovman O, Gilburd B, Zandman-Goddard G, Yehiely A, Langevitz P, Shoenfeld Y. Multiplexed AtheNA Multi-lyte immunoassay for ANA screening in autoimmune diseases. Autoimmunity 2005; 38:105-9.
66. Martins TB, Burlingame R, von Muhlen CA, Jaskowski TD, Litwin CM, Hill HR. Evaluation of multiplexed microsphere immunoassay for detection of autoantibodies to nuclear antigens. Clin Diagn Lab Immunol 2004;11:1054-9.
67. Shovman O, Gilburd B, Barzilai O, Shinar E, Larida B, Zandman-Goddard G, et al. Evaluation of BioPlex ANA screen: analysis of 510 healthy subjects; incidence of natural/predictive autoantibodies. Ann N Y Acad Sci 2005;1050:380-8.
68. Binder SR, Genovese MC, Merrill JT, Morris RI, Metzger AL. Computer-assisted pattern recognition of autoantibody results. Clin Diagn Lab Immunol 2005;12:1353-7.
69. Smith J, Onley D, Garey C, Crowther S, Cahir N, Johanson A, et al. Determination of ANA specificity using the UltraPlex platform. Ann N Y Acad Sci 2005;1050:286-94.
70. Binder SR. Autoantibody detection using multiplex technologies. Lupus 2006;15:412-21.
71. Pang S, Smith J, Onley D, Reeve J, Walker M, Foy C. A comparability study of emerging protein array platforms with established ELISA procedures. J Immunol Methods 2005;302: 1-12.
72. Zandman-Goddard G, Gilburd B, Shovman O, Blank M, Berdichevski S, Langevitz P, et al. The homogeneous multiplexed system: a new method for autoantibody profile in systemic lupus erythematosus. Clin Dev Immunol 2005;12:107-11.
73. Picard FJ, Bergeron MG. Rapid molecular theranostics in infectious diseases. Drug Discov Today 2002;7:1092-101.
74. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Medicine 2006;3:1242-8.
75. Scofield RH. Autoantibodies as predictors of disease. Lancet 2004;383:1544-6.